5:22 PM
 | 
Jun 13, 2013
 |  BC Extra  |  Clinical News

Celltrion presents Phase I data for CT-P13

Celltrion Inc. (KOSDAQ:068270) presented Phase I data comparing its CT-P13 with Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and partner Merck & Co. Inc. (NYSE:MRK) at the European League Against Rheumatism meeting on Thursday. In 250 patients with active ankylosing spondylitis in the Phase I...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >